Dengue fever secondary prevention: Difference between revisions
No edit summary |
m (Changes made per Mahshid's request) |
||
| Line 14: | Line 14: | ||
[[Category:Flaviviruses]] | [[Category:Flaviviruses]] | ||
[[Category:Hemorrhagic fevers]] | [[Category:Hemorrhagic fevers]] | ||
[[Category:Insect-borne diseases]] | [[Category:Insect-borne diseases]] | ||
[[Category:Neglected diseases]] | [[Category:Neglected diseases]] | ||
[[Category:Tropical disease]] | [[Category:Tropical disease]] | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
Revision as of 17:34, 18 September 2017
|
Dengue Fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dengue fever secondary prevention On the Web |
|
American Roentgen Ray Society Images of Dengue fever secondary prevention |
|
Risk calculators and risk factors for Dengue fever secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype DENV-1 contracts serotype DENV-2 or DENV-3, or if someone previously exposed to DENV-3 acquires DENV-2.[1]
References
- ↑ Guzmán MG, Alvarez M, Rodríguez R, Rosario D, Vázquez S, Vald s L; et al. (1999). "Fatal dengue hemorrhagic fever in Cuba, 1997". Int J Infect Dis. 3 (3): 130–5. PMID 10460923.